Diabetes drug may fight heart scarring in High-Risk patients
NCT ID NCT05367063
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study tested whether canagliflozin, a diabetes drug, can reduce scarring in the heart muscle of people with type 2 diabetes who are at high risk for heart problems. 45 participants were randomly assigned to take either canagliflozin or sitagliptin daily. Researchers used MRI scans to measure changes in heart fibrosis over time, aiming to understand how the drug might protect the heart.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Canagliflozin (a diabetes drug) compared to sitagliptin
What this could lead to
If it works, this could show that canagliflozin helps reduce heart scarring, potentially lowering heart failure risk in people with diabetes.
What could go wrong
This is a small, early-phase study with only 45 participants, so results may not apply broadly. The effect on heart scarring is uncertain, and the drug may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200000, China